Cargando…

Survival and associated comorbidities in inclusion body myositis

OBJECTIVE: To evaluate survival and associated comorbidities in inclusion body myositis (IBM) in a population-based, case-control study. METHODS: We utilized the expanded Rochester Epidemiology Project medical records-linkage system, including 27 counties in Minnesota and Wisconsin, to identify pati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Naddaf, Elie, Shelly, Shahar, Mandrekar, Jay, Chamberlain, Alanna M, Hoffman, E Matthew, Ernste, Floranne C, Liewluck, Teerin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Clinical Science
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9071572/ https://www.ncbi.nlm.nih.gov/pubmed/34534271 http://dx.doi.org/10.1093/rheumatology/keab716

Ejemplares similares

Inclusion body myositis: Update on the diagnostic and therapeutic landscape
por: Naddaf, Elie
Publicado: (2022)

Exploring challenges in the management and treatment of inclusion body myositis
por: Skolka, Michael P., et al.
Publicado: (2023)

Correction to: Survival and associated comorbidities in inclusion body myositis
Publicado: (2022)

Diagnostic modelling and therapeutic monitoring of immune-mediated necrotizing myopathy: role of electrical myotonia
por: Triplett, James D, et al.
Publicado: (2020)

Epidemiology, Survival, and Clinical Characteristics of Inclusion Body Myositis
por: Lindgren, Ulrika, et al.
Publicado: (2022)

Adult-Onset Sandhoff Disease in a Filipino Patient: Asymmetric Weakness, Whole HEXB Gene Deletion, and Coexisting MYH7 Pathogenic Variant
por: Beecher, Grayson, et al.
Publicado: (2022)

A Window Into the Myofibrillar Myopathy Proteome
por: Liewluck, Teerin
Publicado: (2021)

Update in inclusion body myositis
por: Machado, Pedro, et al.
Publicado: (2013)

Genetics in inclusion body myositis
por: Rothwell, Simon, et al.
Publicado: (2017)

Detecting dysphagia in inclusion body myositis
por: Cox, F. M., et al.
Publicado: (2009)

Inclusion Body Myositis Treated with Alemtuzumab
por: Sá, Juliana, et al.
Publicado: (2019)

Immune checkpoint inhibitor-associated myopathy: a clinicoseropathologically distinct myopathy
por: Shelly, Shahar, et al.
Publicado: (2020)

Development and validation of a Bayesian survival model for inclusion body myositis
por: Capkun, Gorana, et al.
Publicado: (2019)

Ongoing Developments in Sporadic Inclusion Body Myositis
por: Machado, Pedro M., et al.
Publicado: (2014)

The Low Prevalence of Inclusion Body Myositis in an Outpatient Rheumatology Myositis Cohort
por: Edigin, Ehizogie, et al.
Publicado: (2020)

Anoctamin 5 (ANO5) Muscle Disorders: A Narrative Review
por: Soontrapa, Pannathat, et al.
Publicado: (2022)

Ultrasound can differentiate inclusion body myositis from disease mimics
por: Leeuwenberg, Kristofoor E., et al.
Publicado: (2020)

Evidence of nerve hypertrophy in patients with inclusion body myositis on lower limb MRI
por: Elmansy, Mostafa, et al.
Publicado: (2022)

Reply: Comment on alemtuzumab and inclusion body myositis
por: Dalakas, Marinos C., et al.
Publicado: (2010)

Inclusion body myositis--a case report.
por: Park, S. H., et al.
Publicado: (1996)

Inclusion-Body Myositis Associated with Alzheimer's Disease
por: Levacic, Danijela, et al.
Publicado: (2013)

Inclusion body myositis associated with Sjögren’s syndrome
por: Misterska-Skóra, Maria, et al.
Publicado: (2012)

Proteomic study of sporadic inclusion body myositis
por: Li, Ke, et al.
Publicado: (2014)

17. Inclusion body myositis associated with SLE
por: Jones, Catrin M, et al.
Publicado: (2018)

Immune and myodegenerative pathomechanisms in inclusion body myositis
por: Keller, Christian W., et al.
Publicado: (2017)

Dysphagia as the Presenting Symptom for Inclusion Body Myositis
por: Esteban, Marcus Juan, et al.
Publicado: (2021)

Long‐term strength and functional status in inclusion body myositis and identification of trajectory subgroups
por: Oldroyd, Alexander G. S., et al.
Publicado: (2020)

Sporadic inclusion body myositis: the genetic contributions to the pathogenesis
por: Gang, Qiang, et al.
Publicado: (2014)

Mitochondrial and inflammatory changes in sporadic inclusion body myositis
por: Rygiel, Karolina A., et al.
Publicado: (2015)

Emerging therapeutic options for sporadic inclusion body myositis
por: Alfano, Lindsay N, et al.
Publicado: (2015)

Inclusion body myositis – pathomechanism and lessons from genetics
por: Murnyák, Balázs, et al.
Publicado: (2015)

Clinical, Histological, and Immunohistochemical Findings in Inclusion Body Myositis
por: de Camargo, Leonardo Valente, et al.
Publicado: (2018)

CYLD dysregulation in pathogenesis of sporadic inclusion body myositis
por: Yamashita, Satoshi, et al.
Publicado: (2019)

Inclusion body myositis in a patient with rheumatoid arthritis
por: Tariq, Mohammad, et al.
Publicado: (2018)

Sarcoidosis: Is It a Possible Trigger of Inclusion Body Myositis?
por: Zakaria, Ali, et al.
Publicado: (2017)

Beevor’s sign in a case of inclusion body myositis
por: Sarraf, Payam, et al.
Publicado: (2021)

Inclusion Body Myositis and Neoplasia: A Narrative Review
por: Damian, Laura, et al.
Publicado: (2022)

COVID-19-Induced Sporadic Inclusion Body Myositis
por: Dalal, Fazal, et al.
Publicado: (2022)

Inclusion body myositis: from genetics to clinical trials
por: Nagy, Sara, et al.
Publicado: (2022)

Cytosolic 5′-nucleotidase 1A autoantibody profile and clinical characteristics in inclusion body myositis
por: Lilleker, J B, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_vp6d8ei3lm2e034mae16rbu47b